Skip to content
Medical Health Aged Care

Supporting people living with dementia to vote in the federal election

Dementia Australia 2 mins read

Dementia Australia is encouraging people living with dementia, their families and carers to begin discussions now about voting in the federal election on 3 May to ensure they have the support they need to participate.

“Voting is a fundamental part of our democracy, and it is essential that people living with dementia are supported to make an informed decision,” Professor Buchanan said.

For many people living with dementia, simple support measures can assist them to vote, such as help with arranging a postal vote or assistance in attending a voting centre.”

Professor Buchanan urged people living with dementia, their families and carers to start the conversation now and, where necessary, seek advice from a medical professional.

“It is important that people living with all forms of dementia, their families and carers start the conversation now and where appropriate include their doctor to discuss their capacity to vote,” Professor Buchanan said.

The Australian Electoral Commission (AEC) provides a range of resources, including Easy Read Guides, to help people living with dementia navigate the voting process.

If it is decided that someone is no longer capable of understanding the nature and significance of enrolment and voting, the appropriate form can be completed and submitted through the AEC to remove them from the electoral roll. The medical certificate on the form must be completed and signed by a registered medical practitioner.

Any changes to electoral details must be made before the electoral roll closes at 8pm (AEST) on Monday 7 April.

To further assist people living with dementia, their families and carers with information regarding support to vote for this election, Dementia Australia is hosting a series of information sessions. Click here for details on the sessions and how to join. Visit our website for more information on voting with dementia and a pre-recorded video of the information session.

If someone living with dementia requires assistance at a voting centre or when in contact with the AEC, please call the National Dementia Helpline on 1800 100 500. The National Dementia Helpline is a free call and operates 24 hours a day, seven days a week, 365 days a year.

-Ends-

Dementia Australia is the source of trusted information, education and services for the estimated 433,300 Australians living with dementia, and the more than 1.7 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.


For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

Media contacts: David Gear, Media and Communications Advisor, 0435 515 221, [email protected]

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:
We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.

More from this category

  • Medical Health Aged Care
  • 07/12/2025
  • 01:41
Takeda Pharmaceutical Company Limited

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline NEWARK,…

  • Medical Health Aged Care
  • 06/12/2025
  • 02:11
Arthur D. Little

Arthur D. Little and Vega IT Unveil Joint Venture for Digital Innovation

NEW YORK–BUSINESS WIRE– Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design,…

  • Contains:
  • Medical Health Aged Care, Women
  • 05/12/2025
  • 10:11
Breast Cancer Trials

Bec’s Christmas wish amid cancer treatment

This Christmas, Bec’s wish is for her daughters to never face a breast cancer diagnosis like she has. “The only thing tougher than telling…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.